Brief: Wave Life Sciences Plans To Accelerate Regulatory Engagement With Full Control Of WVE-006
02/02/2026 13:22
Feb 2 (Reuters) - WAVE Life Sciences Ltd WVE.O: WAVE LIFE SCIENCES ANNOUNCES PLANS TO ACCELERATE REGULATORY ENGAGEMENT WITH FULL CONTROL OF WVE-006 FOR ALPHA-1 ANTITRYPSIN DEFICIENCY WAVE LIFE SCIENCES LTD: PLANS TO ENGAGE FDA ON POTENTIAL ACCELERATED APPROVAL PATHWAY FOR WVE-006, WITH REGULATORY FEEDBACK ANTICIPATED MID-2026 WAVE LIFE SCIENCES LTD - DATA FROM 400 MG COHORT ON TRACK FOR Q1 2026 WAVE LIFE SCIENCES LTD: DATA FROM 600 MG SINGLE AND MULTIDOSE COHORTS ARE EXPECTED IN 2026 WAVE LIFE SCIENCES LTD - EXPECTS CASH RUNWAY INTO THIRD QUARTER OF 2028 Source text: ID:nGNX8qMX0r Further company coverage: WVE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Wave Life Sciences
See all newsWave Life Sciences Ltd Reports Results For The Quarter Ended June 30: Earnings Summary
Wave Life Sciences Ltd Expected To Post A Loss Of 31 Cents A Share: Earnings Preview
Wave Life Sciences Q1 revenue jumps, beats analyst estimates
Brief: Wave Life Sciences Announces Hearing On Proposed Redomiciliation To The United States
Brief: Wave Life Sciences Announces Proposed Redomiciliation To The United States